NCT05997615 - Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer | Biotech Hunter

Enrollment

390

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

September 29, 2027

Study Completion Date

September 29, 2027

Conditions

Hormone-refractory Prostate Cancer

Interventions

DRUG

VIR-5500

Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion

COMBINATION_PRODUCT

Enzalutamide

Oral administration

COMBINATION_PRODUCT

Darolutamide

Oral administration

Trial Locations (8)

2010

RECRUITING

Investigational Site Number: 101, Sydney

3000

RECRUITING

Investigational Site Number: 100, Melbourne

28027

RECRUITING

Investigational Site Number: 254, Madrid

28223

RECRUITING

Investigational Site Number: 252, Madrid

31008

RECRUITING

Investigational Site Number: 253, Pamplona

08023

WITHDRAWN

Investigational Site Number: 251, Barcelona

08035

RECRUITING

Investigational Site Number: 250, Barcelona

SM2 5PT

RECRUITING

Investigational Site Number: 300, London

All Listed Sponsors

lead

Vir Biotechnology, Inc.

INDUSTRY